Search results for "AMD"

showing 10 items of 40 documents

VEGF-R2/Caveolin-1 Pathway of Undifferentiated ARPE-19 Retina Cells: A Potential Target as Anti-VEGF-A Therapy in Wet AMD by Resvega, an Omega-3/Poly…

2021

Age-related macular degeneration (AMD) is one of the main causes of deterioration in vision in adults aged 55 and older. In spite of therapies, the progression of the disease is often observed without reverse vision quality. In the present study, we explored whether, in undifferentiated ARPE-19 retinal cells, a disruption of the VEGF receptors (VEGF-R)/caveolin-1 (Cav-1)/protein kinases pathway could be a target for counteracting VEGF secretion. We highlight that Resvega®, a combination of omega-3 fatty acids with an antioxidant, resveratrol, inhibits VEGF-A secretion in vitro by disrupting the dissociation of the VEGF-R2/Cav-1 complex into rafts and subsequently preventing MAPK activation.…

0301 basic medicineMAP Kinase Signaling SystemAngiogenesisQH301-705.5Caveolin 1Drug Evaluation PreclinicalresveratrolResveratrolAMDRetinaArticleCatalysisCell LineVEGF-receptorInorganic ChemistryMacular Degeneration03 medical and health scienceschemistry.chemical_compoundangiogenesis0302 clinical medicinemedicineHumansSecretionPhysical and Theoretical ChemistryBiology (General)Molecular BiologyQD1-999SpectroscopyRetinaomega-3 fatty acidsKinaseOrganic Chemistryocular diseasesRetinalGeneral MedicineVascular Endothelial Growth Factor Receptor-2VEGFIn vitroComputer Science ApplicationsTranscription Factor AP-1Chemistry030104 developmental biologymedicine.anatomical_structurechemistry030220 oncology & carcinogenesisCaveolin 1Cancer researchInternational Journal of Molecular Sciences
researchProduct

Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease

2020

Abstract Background Advanced age-related macular degeneration (AMD) is a leading cause of blindness. While around half of the genetic contribution to advanced AMD has been uncovered, little is known about the genetic architecture of early AMD. Methods To identify genetic factors for early AMD, we conducted a genome-wide association study (GWAS) meta-analysis (14,034 cases, 91,214 controls, 11 sources of data including the International AMD Genomics Consortium, IAMDGC, and UK Biobank, UKBB). We ascertained early AMD via color fundus photographs by manual grading for 10 sources and via an automated machine learning approach for > 170,000 photographs from UKBB. We searched for early AMD loc…

0301 basic medicinegenetic structures610 MedizinGenome-wide association studyMacular Degeneration0302 clinical medicineAdvanced diseaseCD46Genetics (clinical)GeneticsInternational AMD genomics consortium (IAMDGC)ddc:6100303 health sciencesGenome-wide association study (GWAS)3. Good health030220 oncology & carcinogenesisAge-related macular degeneration (AMD)Meta-analysisResearch ArticleGenetic Markerslcsh:Internal medicineUK biobank (UKBB)lcsh:QH426-470Locus (genetics)GenomicsComputational biologyBiologyPolymorphism Single NucleotideGenome-wide association study (GWAS) Meta-analysis Age-related macular degeneration (AMD) Early AMD CD46 TYR International AMD genomics consortium (IAMDGC) UK biobank (UKBB) Machine-learning Automated phenotyping03 medical and health sciencesEarly AMDGeneticsmedicineHumansGenetic Predisposition to DiseaseGenome-wide Association Study (gwas) ; Meta-analysis ; Age-related Macular Degeneration (amd) ; Early Amd ; Cd46 ; Tyr ; International Amd Genomics Consortium (iamdgc) ; Uk Biobank (ukbb) ; Machine-learning ; Automated Phenotypinglcsh:RC31-1245Machine-learning030304 developmental biologyTYRCD46Macular degenerationmedicine.diseaseHuman geneticseye diseasesGenetic architectureMeta-analysislcsh:Genetics030104 developmental biologyGenetic LociCase-Control StudiesAutomated phenotypingHTRA1030221 ophthalmology & optometrysense organsGenome-Wide Association Study
researchProduct

New Highlights of Resveratrol: A Review of Properties against Ocular Diseases

2021

Eye diseases are currently a major public health concern due to the growing number of cases resulting from both an aging of populations and exogenous factors linked to our lifestyles. Thus, many treatments including surgical pharmacological approaches have emerged, and special attention has been paid to prevention, where diet plays a preponderant role. Recently, potential antioxidants such as resveratrol have received much attention as potential tools against various ocular diseases. In this review, we focus on the mechanisms of resveratrol against ocular diseases, in particular age-related macular degeneration, glaucoma, cataract, diabetic retinopathy, and vitreoretinopathy. We analyze, in…

0301 basic medicinegenetic structuresEye DiseasesReviewDiseaseresveratrolAMDResveratrolBioinformaticsAntioxidantsEpigenesis Geneticlcsh:Chemistryangiogenesischemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineSirtuin 1Gene Regulatory Networkslcsh:QH301-705.5Spectroscopy3309.20 Propiedades de Los AlimentosClinical Trials as TopicGeneral MedicineDiabetic retinopathyComputer Science Applicationsdiabetic retinopathycataract3201.09 OftalmologíanutraceuticalCatalysisInorganic Chemistry03 medical and health sciences2302 BioquímicamedicineHumansPhysical and Theoretical ChemistryMolecular BiologypolyphenolsMolecular signalingbusiness.industryocular diseasesOrganic ChemistryeyesMacular degenerationmedicine.diseaseeye diseasesClinical trial030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Gene Expression Regulationchemistry030221 ophthalmology & optometryReactive Oxygen SpeciesbusinessInternational Journal of Molecular Sciences
researchProduct

Results of an Open Clinical Trial of Brofaromine (CGP 11 305 A), a Competitive, Selective, and Short-Acting Inhibitor of MAO-A in Major Endogenous De…

1987

In an open clinical trial the authors treated 18 hospitalized patients suffering from endogenous depression with brofaromine (CGP 11305A), a competitive, selective, and short-acting inhibitor of type A monoamine oxidase (MAO). Four patients were defined as good responders, as they had a final HAMD score of between 0 and 7 points. Four patients were judged as improved, with final HAMD scores of between 8 and 15 points, while the remaining eight patients failed to respond (final HAMD score greater than or equal to 16 points). The major observations were a beneficial influence on drive in most patients, while paranoid symptoms worsened markedly, rendering the substance contraindicated in psych…

AdultBlood PlateletsMaleSerotoninMonoamine Oxidase Inhibitorsmedicine.medical_treatmentSleep REMTyraminePsychotic depressionPharmacologyPersonality AssessmentDexamethasonechemistry.chemical_compoundPiperidinesBrofaromineHamdmedicineHumansPharmacology (medical)Monoamine OxidaseDepression (differential diagnoses)AgedDepressive DisorderChemotherapybiologyElectroencephalographyGeneral MedicineMiddle Agedmedicine.diseaseClinical trialPsychiatry and Mental healthchemistryEndogenous depressionbiology.proteinFemaleMonoamine oxidase APsychologyPharmacopsychiatry
researchProduct

Standardized rater training for the Hamilton Depression Rating Scale (HAMD-17) in psychiatric novices.

2003

Abstract Background: Despite the long and widespread use of the Hamilton Depression Rating Scale (HAMD), standardized reliability studies in inexperienced raters are not available. Methods: Rater training was carried using three videotaped interviews with depressed patients in 21 psychiatric novices who had negligible previous experience with the HAMD. Chance-corrected coefficients of rating agreement with expert standards (weighted κ , ICC) were computed for single items and the total score of the HAMD. Results: The results demonstrate sufficiently high interrater reliability ( κ >0.60) for most of the HAMD items and the total score (ICC=0.57–0.73). Three standardized HAMD training session…

AdultMaleObserver VariationPsychiatric Status Rating ScalesPsychiatrymedicine.medical_specialtyPsychometricsItem analysisDepressionTeachingRater trainingPsychiatry and Mental healthClinical PsychologyInter-rater reliabilityRating scaleSurveys and QuestionnairesHamdmedicineHumansGeneralizability theoryFemalePsychologyPsychiatryDepression (differential diagnoses)Journal of affective disorders
researchProduct

Insight in schizophrenia–course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorder

2012

AbstractBackgroundTo analyse insight of illness during the course of inpatient treatment, and to identify influencing factors and predictors of insight.MethodsInsight into illness was examined in 399 patients using the item G12 of the Positive and Negative Syndrome Scale (“lack of insight and judgement”). Ratings of the PANSS, HAMD, UKU, GAF, SOFAS, SWN-K and Kemp's compliance scale were performed and examined regarding their potential association with insight. The item G12 was kept as an ordinal variable to compare insight between subgroups of patients.ResultsAlmost 70% of patients had deficits in their insight into illness at admission. A significant improvement of impairments of insight …

AdultMaleOrdinal datamedicine.medical_specialtyMedizin03 medical and health sciences0302 clinical medicineTreatment targetsPredictive Value of TestsHamdmedicineHumansPsychiatryPsychiatric Status Rating ScalesPositive and Negative Syndrome ScaleAwarenessmedicine.disease030227 psychiatryPsychiatry and Mental healthInsight into illnessSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychology030217 neurology & neurosurgeryClinical psychologySchizophrenia spectrumEuropean Psychiatry
researchProduct

Comparative analysis of observer depression scales

1985

Abstract The Hamilton Depression Scale (HAMD), Bech Rafaelsen Melancholia Scale (BRMS) and Montgomery Asberg Depression Rating Scale (MADRS) are analyzed according to mean discriminatory power, internal consistency, homogeneity and transferability. The analysis was done separately in different samples of patients with depressive syndromes: a) operationally defined depressive syndrome; b) Major Depressive Disorder (RDC); c) Major Depressive Disorder, endogenous type (RDC). BRMS and MADRS were superior to HAMD in all evaluated aspects. Further, the BRMS was superior to MADRS according to the criteria of homogeneity and transferability.

AdultMalePsychiatric Status Rating ScalesDepressive Disordermedicine.medical_specialtyHamilton depression scalePsychometricsStatistics as TopicTest validityMiddle Agedmedicine.diseaseDiscriminatory powerPsychiatry and Mental healthMontgomery–Åsberg Depression Rating ScaleMelancholiaHamdmedicineHumansMajor depressive disorderFemalemedicine.symptomPsychiatryPsychologyActa Psychiatrica Scandinavica
researchProduct

Differential effects of the enantiomers R(-) and S(+) oxaprotiline on major endogenous depression, the sleep EEG and neuroendocrine secretion: studie…

1993

The effects of the optically active enantiomers of oxaprotiline (OXP), R(-) OXP and S(+) OXP, on depressive symptomatology and the sleep EEG were investigated in two separate exploratory studies. In addition, the neuroendocrine profile of both compounds was characterized in normal controls. In the patients treated with a daily oral dose of 150 mg S(+) OXP we found a Hamilton depression score that decreased from 29.1 +/- 1.8 (SEM) on day 0 to 14.7 +/- 3.2 on day 28 (P0.01). Six patients were judged to be full responders (HAMD score 0-7 points), three were improved (HAMD score 8-15) and four were nonresponders (HAMD score16). The therapeutic effect achieved with 150 mg R(-) OXP daily was less…

AdultMalemedicine.medical_specialtyHydrocortisoneSleep REMchemistry.chemical_compoundNorepinephrineInternal medicineHamdmedicineHumansPharmacology (medical)SecretionTestosteroneBiological PsychiatryTestosteroneAgedPharmacologyPsychiatric Status Rating ScalesDepressive DisorderNeurosecretionPenile ErectionTherapeutic effectOxaprotilineElectroencephalographyStereoisomerismMiddle AgedProlactinAntidepressive AgentsProlactinPsychiatry and Mental healthEndocrinologyNeurologychemistryMaprotilineGrowth HormoneEndogenous depressionFemaleNeurology (clinical)EnantiomerPsychologySleepEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Outcome of suicidal patients with schizophrenia: results from a naturalistic study.

2010

Schennach-Wolff R, Jager M, Seemuller F, Obermeier M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Moller H-J, Riedel M. Outcome of suicidal patients with schizophrenia: results from a naturalistic study. Objective:  Purpose was to assess suicidality before and at the time of admission in patients with schizophrenia and compare outcome differences. Method:  Biweekly PANSS (Positive and Negative Syndrome Scale), HAMD (Hamilton Depression Rating Scale) and UKU (Udvalg for Klinske Undersogelser Side Effect Rating Scale) ratings were evaluated in 339 in-patients with schizophrenic spectrum disorder…

AdultMalemedicine.medical_specialtyPsychosisMedizinPoison controlSuicide AttemptedComorbidityAkathisiaCohort StudiesHospitals University03 medical and health sciencesYoung Adult0302 clinical medicineRating scaleRisk FactorsGermanyHamdmedicineHumansPsychiatryPsychiatric Status Rating ScalesDepressive Disorder MajorPositive and Negative Syndrome ScaleIncidenceMiddle Agedmedicine.diseaseComorbidityHealth Surveys3. Good health030227 psychiatryPsychiatry and Mental healthCross-Sectional StudiesTreatment OutcomeSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychology030217 neurology & neurosurgeryAkathisia Drug-InducedAntipsychotic AgentsActa psychiatrica Scandinavica
researchProduct

hs-CRP Predicts Improvement in Depression in Patients With Type 1 Diabetes and Major Depression Undergoing Depression Treatment: Results From the Dia…

2016

hs-CRP is elevated in depression (1), but evidence on decreases of hs-CRP during depression treatment or the role of hs-CRP in the prediction of response to depression treatment is still controversial (2,3). To date, no study has examined this association in patients with diabetes. As elevated hs-CRP increases the risk of diabetes complications in diabetes (4), we aimed to explore hs-CRP in patients with diabetes and major depression undergoing depression treatment based on the data of the Diabetes and Depression (DAD) study (5). Participants were randomized to 12 weeks (short-term phase) of diabetes-specific group cognitive behavioral therapy or sertraline treatment and followed up for 15 …

Advanced and Specialized NursingSertralineType 1 diabetesmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType 2 diabetesmedicine.disease030227 psychiatryCognitive behavioral therapy03 medical and health sciences0302 clinical medicineInterquartile rangeDiabetes mellitusInternal medicineHamdInternal MedicineMedicinebusinessPsychiatry030217 neurology & neurosurgeryDepression (differential diagnoses)medicine.drugDiabetes Care
researchProduct